Bajaj Healthcare Ltd delivered a robust financial turnaround in Q1 FY2027, with consolidated profit after tax (PAT) from continuing operations rising 14.1% year-on-year to ₹13.9 crore for the quarter ended June 30, 2026, compared with ₹12.2 crore in the corresponding period last year. According to reports from CNBC TV18, this marks a significant recovery from the previous quarter's loss, which was primarily attributed to exceptional expenses. The latest data from Business Standard confirms this strong performance with standalone net profit rising 15.81% to ₹13.70 crore in the June 2026 quarter, demonstrating consistent improvement across both consolidated and standalone financial metrics.
The pharmaceutical company demonstrated strong operational performance with revenue from operations increasing 11.3% to ₹165.6 crore from ₹148.8 crore a year earlier. As reported by CNBC TV18, the company's EBITDA grew 17.3% year-on-year to ₹28.8 crore from ₹24.5 crore, while EBITDA margin expanded to 17.4% from 16.5%, indicating improved operating profitability and operational efficiency. The latest Business Standard data shows operating profit margin (OPM) at 17.36% compared to 16.47% in the previous year, while PBDT increased 16% to ₹23.47 crore from ₹20.16 crore, and PBT rose 13% to ₹16.46 crore from ₹14.52 crore, reflecting enhanced operational leverage across all key profitability metrics.
The March quarter had included an exceptional expense of ₹33.2 crore, primarily due to the reversal of income recognised in an earlier period under a technical know-how arrangement after delays linked to geopolitical instability in the West Asia. According to CNBC TV18, this exceptional expense significantly impacted the previous quarter's performance, making the current quarter's recovery all the more impressive. The latest financial data confirms this exceptional expense was a one-time impact that has now been absorbed, allowing for the sustained profitability growth in the current quarter.
On a sequential basis, the company showed strong improvement with profit after tax from continuing operations at ₹13.9 crore, compared with a loss of ₹19.4 crore in the March quarter. As reported by CNBC TV18, profit before tax came in at ₹16.5 crore, compared with a loss before tax of ₹20.8 crore in the previous quarter. Revenue from operations also increased 8.2% from ₹153.1 crore in the March quarter to ₹165.6 crore. The latest Business Standard data reinforces this sequential improvement, showing revenue growth of 11.28% to ₹165.63 crore from the previous quarter's ₹148.84 crore, indicating sustained momentum in business operations.
The market responded positively to the strong quarterly results, with shares of Bajaj Healthcare closing at ₹391, up 4.56% from the previous close on the National Stock Exchange. According to CNBC TV18, the company operates in the pharmaceuticals segment, manufacturing active pharmaceutical ingredients, formulations and nutraceutical products, positioning it well for continued growth in the healthcare sector. The latest market performance data from Business Standard confirms this positive investor sentiment, reflecting confidence in the company's operational turnaround and sustained growth trajectory in the pharmaceutical sector.
